Table 4.
Multilevel modeling regression coefficients [b (se)] for each of the eight primary study outcomes as a function of only the covariates
| FACT-G PWB | FACT-G SWB | FACT-G EWB | FACT-G FWB | EPIC urinary bother | EPIC urinary function | EPIC sexual bother | EPIC sexual function | PROMIS Depn | FSI | MPQ | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Intercept | 23.32* (0.35) | 20.50** (0.36) | 20.75** (0.34) | 20.75** (0.40) | 76.62** (1.55) | 83.64** (1.58) | 54.60** (3.31) | 11.21** (1.19) | 45.31** (0.69) | 8.85** (0.91) | 5.45** (0.51) |
| Age | 0.15** (0.04) | − 0.01 (0.04) | 0.08* (0.04) | 0.06 (0.04) | 0.14 (0.17) | 0.14 (0.17) | 1.24** (0.35) | − 0.19 (0.12) | − 0.12 (0.07) | − 0.09 (0.10) | − 0.20** |
| Comorbidity | − 1.31** (0.21) | 0.01 (0.22) | − 0.44* (0.21) | − 0.82** (0.24) | − 2.69** (0.95) | − 2.13* (0.97) | 0.48 (1.99) | − 0.60 (0.72) | 1.26* (0.42) | 2.75** (0.56) | 1.71** (0.31) |
| Days between session 10 & T2 | 0.01 (0.01) | 0.01 (0.01) | 0.01 (0.01) | 0.01 (0.01) | 0.04 (0.04) | 0.10* (0.04) | 0.02 (0.07) | − 0.02 (0.03) | − 0.02 (0.02) | − 0.03 (0.02) | 0.01 (0.01) |
| Years since dx | 0.08 (0.06) | − 0.02 (0.06) | 0.01 (0.06) | 0.09 (0.07) | 0.53 (0.27) | − 0.03 (0.28) | 0.25 (0.57) | − 0.01 (0.21) | 0.09 (0.12) | − 0.23 (0.16) | − 0.08 (0.09) |
| Time since ADT | 0.03 (0.08) | 0.07 (0.08) | < 0.01 (0.05) | 0.07 (0.09) | < 0.01 (0.30) | − 0.03 (0.28) | 0.54 (0.69) | − 0.12 (0.25) | − 0.09 (0.13) | − 0.01 (0.22) | − 0.02 (0.12) |
| Group strat | 0.94 (0.60) | − 0.19 (0.63) | 0.28 (0.59) | 0.34 (0.69) | − 1.70 (2.67) | − 6.68* (2.73) | − 16.45** (5.64) | 1.86 (2.03) | 1.78 (1.18) | − 3.14* (1.58) | − 1.18 (0.88) |
| Marital status | 0.05 (0.69) | 2.41** (0.72) | 0.31 (0.69) | 0.43 (0.79) | − 0.24 (3.09) | 0.35 (3.16) | 16.79* (6.50) | − 3.37 (2.33) | − 1.81 (1.37) | − 3.58 (1.82) | − 2.24* (1.01) |
| Race | 0.18 (0.67) | 1.34 (0.71) | − 1.89** | 0.73 (0.78) | 0.24 (3.02) | − 2.61 (3.09) | − 6.07 (6.36) | − 9.00** (2.27) | 2.95* (1.34) | 2.78 (1.78) | − 0.53 (0.99) |
| Employment | 0.84 (0.64) | − 0.16 (0.67) | (0.67) − 0.07 (0.64) | 1.56* (0.74) | 3.53 (2.86) | 1.05 (2.93) | 4.07 (6.04) | − 1.48 (2.16) | − 0.64 (1.27) | 1.32 (1.68) | − 0.45 (0.94) |
| Income | − 0.68 (0.77) | − 0.11 (0.80) | − 0.87 (0.76) | − 0.36 (0.88) | − 2.48 (3.44) | − 1.60 (3.52) | − 3.29 (7.26) | − 0.29 (2.60) | 3.44* (1.52) | 3.37 (2.02) | 2.13 (1.12) |
| Treatment received | − 0.42 (0.34) | − 0.68 (0.35) | − 0.29 (0.22) | − 0.43 (0.40) | − 0.08 (1.34) | − 0.13 (1.27) | 3.63 (3.20) | − 0.41 (1.16) | 1.00 (0.60) | 1.52 (0.98) | 0.69 (0.56) |
p< 0.05
p < 0.01
Time since ADT = months since most recent androgen deprivation therapy treatment. Group strat = group stratification as metastatic or advanced disease. Years since dx = years since initial prostate cancer diagnosis. PROMIS Depn = Patient-Reported Outcomes Measurement Information System Depression. Age, comorbidity, days between session 10 & T2, years since dx, and time since ADT were all grand mean centered. Group stratification was coded 0.5, advanced disease; − 0.5, metastatic disease; marital status was coded 0.5, married or living equivalently; − 0.5, not married; race was coded 0.5, White; − 0.5, Other; employment was coded 0.5, working full- or part-time; − 0.5, not working; income was coded 0.5, ≥ $35,000; − 0.5, < $35,000; treatment received was coded: 0.5, some treatment other than ADT received prior to timepoint; − 0.5, no treatment other than ADT received prior to timepoint